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Introduction
Periarhritis humeroscapularis (PHS) is chronic periarti-
cular inflammation of the humeral joint encompassing
soft tissues, with extraskeletal ossification, shoulder pain
and joint disability.
The treatment of periarhritis humeroscapularis
causes many controversies due to the unsatisfactory
results of different treatments modalities.
A number of treatment methods are applied in this
disease. The most popular is pharmacological treatment
using anti-inflammatory non-steroid drugs applied in oral
[1] and topical form [2]. Other, rarely applied kinds of
pharmacological treatment include a form of immuno-
therapy using thymopentin [3] and biphosphonate therapy
reducing extra skeletal calcification [4].
Another commonly performed treatment modality is
percutaneus injection of steroids and/or local anesthetics
used as intra-articular injections [5] and nerve blocks [6].
This is an effective and relatively low-priced treatment
modality, which allows to achieve satisfactory, but only
temporary results, significantly better than the placebo
effect [7].
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M a t e r i a l  a n d  m e t h o d.  30 patients irradiated because of PHS (1 Gy per fraction up to 6 Gy). Follow-up ranged from 1
to 216 months. The arm mobility and pain relief were assessed at the completion of radiotherapy and during follow-up
examinations. Correlation between some biological factors evaluated before radiotherapy and the aforementioned endpoints
was assessed using Spearman’s test. 
R e s u l t s.  The mean degree of pain relief ranged from 42% to 93%. Mean improvement of arm abduction, flexion and
reflexion angles ranged from 24° to 83°, from 47° to 91° and from 4° to 13°, respectively. The sole prognostic factor found in
this study was the degree of orthopedic disability before the treatment. Small impairment at the onset correlated with
significant improvement after radiotherapy. No radiation toxicity or secondary malignancies were observed. 
C o n c l u s i o n.  Radiotherapy of PHS is an effective, safe and economical treatment modality, which could form an
alternative for standard orthopedic and pharmacological treatment in recurrent or persistent disease.
SkutecznoÊç radioterapii w leczeniu zespo∏u bolesnego barku
M a t e r i a ∏  i m e t o d a.  Przeanalizowano wyniki leczenia grupy 30 chorych na PHS, napromienianych dawkà frakcyjnà 1 Gy
do dawki ca∏kowitej 6 Gy. Czas obserwacji zawiera∏ si´ w przedziale od 1 do 216 miesi´cy. Oceniano stopieƒ ustàpienia bólu
oraz ruchomoÊç w stawie ramiennym przy zakoƒczeniu leczenia oraz podczas kolejnych kontroli. Zale˝noÊci pomi´dzy nie-
którymi czynnikami biologicznymi, a uprzednio wspomnianymi ocenianymi cechami sprawdzano przy u˝yciu testu Spearmana. 
W y n i k i.  Âredni stopieƒ ustàpienia bólu zawiera∏ si´ w przedziale od 42% do 93%. Kàt poprawy odwodzenia, zginania i pro-
stowania ramienia wyniós∏ odpowiednio od 24° do 83°, od 47° do 91° oraz od 4° do 13°. Jedynym znalezionym czynnikiem pro-
gnostycznym by∏ stopieƒ niesprawnoÊci w stawie ramiennym przed rozpocz´ciem radioterapii – niewielka niesprawnoÊç wià-
za∏a si´ z du˝à poprawà po leczeniu. Nie zaobserwowano ˝adnych objawów ubocznych, ani wtórnych nowotworów w czasie
obserwacji.
W n i o s e k.  Radioterapia zespo∏u bolesnego barku jest skutecznà, bezpiecznà i wzgl´dnie tanià metodà leczenia, mogàcà byç
alternatywà dla chirurgicznych i farmakologicznych metod leczenia w nawrotowych i przetrwa∏ych postaciach tego schorzenia.
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Surgery is used relatively rarely, because of the
complex nature of PHS and due to the limited efficacy of
this method. For these reasons surgical treatment is
applied rather as a form of anaesthetic treatment (dener-
vation), rather than to alter the anatomy of the shoulder
region [8, 9].
In painful cases without significant shoulder dys-
function superficial and deep acupuncture may be
performed [10].
Another rarely used treatment modality for PHS,
which, however, offers functional improvement and pain
relief, is extracorporeal shock-wave therapy [11].
Due to the limited efficacy of these treatment
modalities, a relatively important treatment method,
despite the non-malignant character of this disease, is
radiotherapy. Radiotherapy in case of PHS has been
performed from the first half of the last century and until
the present time, and it remains a quite popular choice in
such clinical circumstances [12-16]. The application of
PHS radiotherapy is based on its high efficacy (pain relief
and arm mobility improvement in more than 80% [14]
and mean pain relief exceeding 80% [16]) and on its
safety (application of small fraction doses ≤1 Gy and lack
of adverse effects [14-16]).
In this kind of radiotherapy the anti-inflammatory
effect is the basic issue [17-19]. The mechanism of this
effect is complicated an, to a great extent unclear. It is
probably based on phenomena completely different than
those, which are used in classic oncological radiobiology.
There is no evidence to prove that radiobiological effects
used in benign disease radiotherapy depend upon the
inhibition of clonogenic cell repopulation [20]. The anti-
inflammatory effect of low fraction doses is probably
based on the modulation of E-selectin liberation and the
activation of endothelial cells, which decreases leukocyte
adhesion [17], on blocking the oxidative burst in
macrophages [19] and on blocking nitric oxide synthase
expression in irradiated tissues [18].
Aim of the study
The aim of the study was to assess the value of radio-
therapy in the treatment of patients with periarthritis
humero-scapularis (PHS).
Material
The material consisted of 30 patients suffering from periarthritis
humero-scapularis (PHS) (13 women and 17 men); (age: 32 – 76
years; mean 59). The time from the onset of the disease to the
start of radiotherapy ranged from 1 to 120 months (mean 18).
Eight patients had concomittant cancer and another five had
been previously treated because of neoplastic disease. Two
patients had haemangiomas of the cervical vertebrae. In 15 cases
the disease was located in the right; and in 15 – in the left
shoulder. In 32% of cases the pain of the shoulder rendered
sleep difficult. Before radiotherapy 19% of patients took non-
steroid anti-inflammatory drugs, 12% – tramadol and 8% –
narcotics. Three of these patients were previously treated by
periarticular steroid injections, and two – by physiotherapy. The
mean degrees of arm abduction, flexion and reflexion at the
treatment beginning were respectively 85°, 83° and 31°.
Patients were irradiated between November 1999
and September 2003 at the Department of Radiotherapy of the
M. Sklodowska-Curie Memorial Cancer Centre and Institute
of Oncology in Gliwice. All were treated from two opposite
(AP-PA) fields, using gamma 60Co beams, 1 Gy per fraction,
up to a total dose of 6 Gy. The irradiated fields comprised
the shoulder and the surrounding soft tissues (Figure 1). The
mean area of the irradiated field was 106 cm2 (range from
42 cm2 to 189 cm2) and the mean thickness of the shoulder was
14 cm.
Follow up ranged from 1 to 216 months (mean 54).
Method
All patients were examined before radiation treatment, at the
end of radiotherapy and on week 1 and 7 and month 6, 12 and 24
after treatment complation. Some patients were controlled
longer. During examination the angle of arm abduction, flexion
and reflexion were measured and the degree of pain relief was
expressed in percentages, as compared to the level from before
the onset of radiotherapy. The impact of shoulder pain on sleep
and the intake of analgesics was evaluated
Means and ranges of the abduction, flexion and reflexion
angles of arm and the percentages of pain relief evaluated during
particular controls and during the last control were calculated.
The percentages of patients with pain relief, with major
pain relief (≥50%) and with complete pain relief were calculated
at the end of radiotherapy and during the follow-up exami-
nations.
The percentages of patients with significant improvement
(≥20°) of arm abduction at the end of radiotherapy and during
following controls were calculated.
The character of data distribution was evaluated using the
Shapiro-Wilk test.
Correlation between patient age, symptom duration, and
the abduction, flexion and reflexion angles were evaluated before
radiotherapy, pain decrease at the end of radiotherapy and
abduction, flexion, reflexion angles and level of pain relief was
evaluated during follow-up (analysis: Spearman’s test).
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Figure 1. The irradiated field in the case of PHS
Results
The mean abduction angle before radiotherapy was 85°
(range: 10° – 180°). The mean flexion and reflexion angles
before the treatment were 83° and 31°, and ranged from
5° to 180° and from 5° to 90°, respectively.
Means, ranges of pain relief degrees and angle
improvements are presented in Table I.
At the end of radiotherapy pain rendered sleep
difficult in 15% of cases, one week later – in 6% and
seven weeks after radiotherapy – in 7%, six months after
the treatment in 8%, 12 months after the treatment in
8% and during the final control – in 4% of cases.
Evaluation of sleep disturbances and analgesic intake
two years after radiotherapy was neglected because of
poor data.
The analgesic intake during follow-up is presented in
Table II.
The percentages of patients with different degrees of
pain relief during follow-up are presented in Table III.
Significant improvement of arm abduction (≥20°) at
the end of radiotherapy was noted in 44% of patients.
In the following control examinations these percentages
were 31%, 31%, 57%, 50% and 41% during control
performed one and seven weeks, and six and twelve
months after radiotherapy, and during the final control,
respectively.
Spearman test showed, at the end of radiotherapy,
statistically significant correlations between abduction,
flexion angles and abduction angle before the treatment
(p=0.0007, R=0.76, p=0.004, R=0.85 respectively),
reflexion angle and reflexion angle before the treatment
(p=0.045, R=0.68).
One week later correlations between pain relief and
pain relief at the end of radiotherapy (p=0.02, R=0.5),
abduction angle and abduction, flexion, reflexion angles
before the treatment, pain relief at the end of radio-
therapy (p=0.000009, R=0.92, p=0.046, R=0.72,
p=0.008, R=0.84, p=0.03, R=0.58 respectively), flexion
angle and abduction, reflexion angles before the treat-
ment (p=0.00004, R=0.98, p=0.039, R=0.73 respec-
tively), were found.
Seven weeks after radiotherapy correlations between
abduction angle and reflexion angle before the treatment
(p=0.001, R=0.93), flexion angle and abduction, reflexion
angles before the treatment (p=0.047, R=0.71, p=0.0498,
R=0.75 respectively), reflexion angle and duration of
symptoms (p=0.013, R=0.75), were found.
51
Table I. Means and ranges of  pain relief  and abduction, flexion and reflexion angles during control examinations
Measured Time of control
feature name Radiotherapy  Week 1 after Week 7 after Month 6 after Month 12 after Month 24 after Final control
completion treatment treatment treatment treatment treatment
Pain relief 42% 70% 77% 80% 93% 78% 74% 
(0-100%) (0-100%) (0-100%) (20-100%) (50-100%) (30-100%) (0-100%)
Abduction angle 109° 111° 132° 148° 168° Too poor data 142° 
(30-180°) (30-180°) (15-180°) (50-180°) (120-180°) (30-180°)
Flexion angle 130° 133° 131° 164° 174° 153° 
(30-180°) (30-180°) (15-180°) (90-180°) (150-180°) (30-180°)
Reflexion angle 35° 35° 35° 44° 42° 37° 
(10-50°) (10-50°) (10-45°) (30-45°) (30-45°) (10-45°)
Table II. Analgesic intake during follow-up
Drug Percentage of patients
Radiotherapy Week 1 after Week 7 after Month 6 after Month 12 after Final control
completion irradiation irradiation irradiation irradiation
Non-steroid anti-inflammatory drugs 13% 19% 6% 7% 11% 4%
Tramadol 6% 12 .5% 12% 13% 11% 11%
Narcotics* 6% 12 .5% 6% 13% 33% 8%
* in all cases narcotis were taken by patients with active neoplastic disease because of cancer pain provoked by cancer
Table III. Percentage of patients with different degrees of pain relief
during follow-up
Degree Any pain relief Major pain relief Complete 
of pain relief (50≤) pain relief
Radiotherapy 77% 50% 12%
completion
Week 1 after 91% 83% 39%
radiotherapy
Week 7 after 95% 84% 37%
radiotherapy
Month 6 after 100% 87% 47%
radiotherapy
Month 12 after 100% 100% 78%
radiotherapy
Month 24 after 100% 80% 40%
radiotherapy
Final control 90% 73% 47%
Six months after treatment completion we found
only one statistically significant correlation i.e. that
between pain relief and the reflexion angle before the
treatment (p=0.04, R=0.89).
An analysis of correlations during the last control
showed statistical significance between pain relief and
patient age (p=0.04, R=0.39), abduction angle and
abduction, reflexion angles before the treatment
(p=0.013, R=0.6, p=0.01, R=0.73 respectively), flexion
angle and abduction angle before the treatment (p=0.046,
R=0.54), reflexion angle and abduction, reflexion angles
before the treatment (p=0.026, R=0.59, p=0.04, R=0.63,
respectively).
No acute and late radiation toxicity or secondary
malignancies were observed.
Discussion
Pa i n  r e l i e f
Our results presented in this paper are similar to those
obtained earlier. In a paper published in 2001 [16] we
reported pain relief at a level of 27%, 72% and 85% at
the end of radiotherapy, one and seven weeks later
respectively. These results were observed in a group of
PHS patients irradiated identically as in the present study.
It is rather difficult to compare our results with those
published in literature. The reason for this situation arises
from the different evaluation criteria used by different
authors, however a majority of researchers report signi-
ficant pain relief. Keilholz described significant pain
reduction in 81% of patients, and complete pain relief
in 49% of patients irradiated with two 3 Gy courses,
0.5 Gy per fraction up to 6 Gy of total dose [14]. He also
reported major pain relief in 16% of cases and complete
pain relief in 14% of patients irradiated with two 6 Gy
courses, 1 Gy per fraction up to 12 Gy [15]. Seegen-
schmiedt reports similar results – 75% of cases with major
relief and 46% of cases with complete relief after two
series of 6x0.5 Gy (total dose 6 Gy) [21].
In view of the previously cited results [14], and
results described in this article (73-100% of major effect,
i.e. pain relief ≥50%, and 37-78% of complete pain relief,
depending upon the time of follow-up) we could expect
the negative impact of an increased total dose on the
degree of pain relief. Other authors also report better
values of pain relief – from 73 to 76% [12, 13]. On the
other hand Valtonen et al. have presented a double blind
trial based on 104 patients divided in two groups: radio-
therapy versus sham irradiation, in which no gain from
this treatment was found (improvement in 59% and 65%
of cases respectively) [22]. This publication suggests the
lack of a radiotherapy-dependant anti-inflammatory
effect, but the relatively low percentage of irradiated
patients with pain relief does call for attention.
O r t h o p e d i c  i m p r o v e m e n t
Despite the excellent results as regarding pain relief, the
decrease of orthopedic disability observed among our
patients was smaller than that described in other articles.
Kelholz reports the percentage of patients with marked
mobility improvement (abduction at least 20° more than
before treatment) as equal to the percentage of patients
with marked pain relief, i.e. 81% [14]. Our results are
not as good – according to controls – from 31% to 57%,
and are similar to the results which we have published
previously (17%-60%) [16]. The exact assessment of
orthopedic changes after PHS irradiation based on the
published literature and their comparison is difficult
because of different endpoints used in the different
studies. In some of them the arm mobility is evaluated as
a percentage of improvement [14, 16], in others it is
evaluated on special orthopedic scales, for example acc. to
the Constant and Murley score [15, 21].
R a d i o t h e r a p y  m o d a l i t i e s
A majority of contemporary irradiation schemes used in
radiotherapy of benign inflammatory diseases is based
on the Trott concept that the best effect could be achieved
with a fraction dose of ≤1 Gy [20]. Only such a small
fraction dose assures all the anti-inflammatory effects of
irradiation, such as leukocyte adhesion decrease, blocking
the oxidative burst in macrophages and blocking nitric
oxide synthase expression in irradiated tissues [17-20].
Higher fraction doses (especially those exceeding 2 Gy),
may even increase inflammation in the irradiated tissues
(acute radiation toxicity). This is the reason why the most
popular PHS radiotherapy schemes are 6x1 Gy or
12x0.5 Gy [14, 16]. The sequences of fraction doses
delivery are different. The total dose could be delivered as
five times a week [16] or a three times a week irradiation
up to 6 Gy given in two series of 3 Gy with an 8-week
gap [14]. Some papers report irradiation to higher dose
(12 Gy). For example Keilholz irradiated patients three
times a week using 1 Gy fraction doses up to 12 Gy
delivered in two 6 Gy series [15]. Seegenschmiedt
reported radiotherapy delivered three times a week in
0.5 Gy fractions up to a 12 Gy total dose given in two
series [21]. Higher total doses, such these in two last
aforementioned publications, exceeding 6 Gy, are not
recommended by Trott, because of the plateau-like effect
appearing in this kind of radiotherapy [20]. These
variations may explain the differences in pain relief
observed after different total doses described in the first
part of the discussion.
P r o g n o s t i c  f a c t o r s
Symptom duration, the independent prognostic factor
reported in literature [13, 15, 21] was not confirmed on in
our study. We did not observe the negative impact of
disease duration on treatment results understood as pain
relief or functional improvement.
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The only one prognostic factor found in this study
was the degree of orthopedic disability before the onset of
treatment. Slight impairment at the beginning correlated
with greater improvement after radiotherapy.
A d v e r s e  e f f e c t s
We did not observe any local radiation injuries, neither
acute nor late and neither are they reported in the
literature. The only widely discussed issue, referred to in
numerous publications, is the probability of carcinogenesis
[12, 15, 16, 21, 23]. There were no secondary malignancies
in the irradiated patient group, but the relatively short
follow-up (mean 54 months) appears to be inadequate
for such an assessment. The quite common statement
regarding the high risk of carcinogenesis after radio-
therapy for benign diseases is rather an archetype based
on observations made in the course of the radiation
treatment of Bechterew’s disease – i.e. radiotherapy
delivered in a huge volume to adolescent patients and
comprising the bone marrow of the spine [21, 24].
Considering the small total dose delivered for PHS, the
relatively small target volume, the patient age (mean:
59 yrs) and the fact that literature data fails to confirm
the high risk of carcinogenesis we should not fear
the development of malignancies secondary after this
treatment [16, 21, 23].
E c o n o m i c a l  a s p e c t s
It is extremely difficult to discuss the economical aspects
of different treatment modalities without the context of
the insurance system. Radiotherapy cost calculation is
probably different in different countries. Generally,
radiotherapy is considered to be an expensive treatment
modality. However, such a statement is true for radical
conformal oncological therapy, while short, six fraction
irradiation from two opposite fields is considerably less
expensive. If we consider the lengthy treatment with non-
steroid anti-inflammatory drugs or repeated invasive
procedures such as intra- or periarticular injections, the
overall cost of radiotherapy would appear rather
encouraging.
Conclusion
Basing on our results and discussion we may conclude
that radiotherapy of periarthritis humeroscapularis is an
effective, safe and relatively inexpensive treatment
modality, which could be considered as an alternative to
standard orthopedic and pharmacological treatment in
case of recurrent or persistent disease.
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